NASDAQ:CGEM Cullinan Therapeutics Q3 2025 Earnings Report $14.86 +0.33 (+2.24%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cullinan Therapeutics EPS ResultsActual EPS-$0.77Consensus EPS -$0.95Beat/MissBeat by +$0.18One Year Ago EPSN/ACullinan Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$12.50 millionBeat/MissN/AYoY Revenue GrowthN/ACullinan Therapeutics Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time7:00AM ETUpcoming EarningsCullinan Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Cullinan Therapeutics Earnings HeadlinesCullinan (NASDAQ: CGEM) starts zipalertinib NDA with up to $100 million3 hours ago | americanbankingnews.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Moderate Buy" from BrokeragesOctober 2 at 2:44 AM | americanbankingnews.comMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of October 31st. See which stocks his AI research platform is flagging right now.October 2 at 1:00 AM | TradeSmith (Ad)Cullinan Therapeutics Initiates FDA NDA Submission for Zipalertinib Combo in First-Line EGFR Exon 20 Insertion NSCLC Following Phase 3 REZILIENT3 ResultsOctober 1 at 7:31 PM | quiverquant.comQNew Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review ProgramOctober 1 at 7:30 PM | globenewswire.comCullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune DiseasesSeptember 29 at 8:00 AM | seekingalpha.comSee More Cullinan Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cullinan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cullinan Therapeutics and other key companies, straight to your email. Email Address About Cullinan TherapeuticsCullinan Therapeutics (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs. Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses. The company also evaluates additional internally developed and partnered programs across oncology and immunology. Founded in 2016 as Cullinan Oncology, the company changed its name to Cullinan Therapeutics in 2024 to reflect its expanding focus beyond oncology. The company is headquartered in Boston, Massachusetts, and conducts clinical development activities intended to support potential commercialization in global markets.View Cullinan Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
